We support suppliers globally.
At Achilles, we connect suppliers to over 860 leading buyer organisations in 11 industry sectors globally to create efficient networks of highly qualified businesses.
Our dedicated teams support suppliers in completing the online pre-qualification questionnaire that validates your credentials to an entire community of relevant buyers in one go.
We are active in eight major industry sectors, and continue to seek opportunities for expanding our portfolio. We are exploring opportunities with other companies in different sectors, with a view to bringing Achilles services to a wider audience.
At Achilles, we connect suppliers to over 860 leading buyer organisations in 11 industry sectors globally to create efficient networks of highly qualified businesses.
Our dedicated teams support suppliers in completing the online pre-qualification questionnaire that validates your credentials to an entire community of relevant buyers in one go.
We are active in eight major industry sectors, and continue to seek opportunities for expanding our portfolio. We are exploring opportunities with other companies in different sectors, with a view to bringing Achilles services to a wider audience.
Location: United Kingdom, England, Abingdon
Employees: 501-1000
Phone: +44 1235 861118
Founded date: 1990
Investors 1
| Date | Name | Website |
| - | Hg | hgcapital.... |
Mentions in press and media 8
| Date | Title | Description |
| 20.03.2025 | Mark Kleinman: CMA revamp to spur boom for M&A bankers | Mark Kleinman is Sky News’ City Editor and the man who gets the Square Mile talking in his weekly City AM column. This week, he tackles changes at the CMA, Achilles’ new target, and a logistics funding boost. Will there even be a competitio... |
| 02.09.2024 | Runergy to Unveil High-Efficiency PV Modules at RE+ 2024 in Anaheim | ANAHEIM, Calif., Sept. 2, 2024 /PRNewswire/ -- From September 10-12, 2024, Runergy, a leading solar energy company and a BNEF Tier 1 PV module manufacturer, will showcase its latest high-efficiency photovoltaics (PV) modules at Booth 63000 ... |
| 06.04.2021 | ACHILLES THERAPEUTICS PLC Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering | LONDON, April 06, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the closing of its previously annou... |
| 31.03.2021 | Bausch Health sells off Amoun for $740M; Achilles debuts on Nasdaq with $175.5M IPO | Looking to pay down debt ahead of the big Bausch + Lomb spinoff, Bausch Health CEO Joseph Papa has struck a deal to sell one of its units in Egypt for $740 million. Abu Dhabi-based holding company ADB is handing over the cash for Am... |
| 19.11.2020 | Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours | Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours - Financing includes leading US-based life science investors OrbiM... |
| 03.09.2019 | Achilles raises £100M for personalized T cell solid tumor trials W h i t e p a p e r Weighing the Costs: | Achilles Therapeutics has raised a £100 million ($120 million) series B round. The financing sets Achilles up to run human proof-of-concept studies of its personalized T-cell therapies in two types of solid tumors. Sponsored by Agilent Tech... |
| 03.09.2019 | Achilles raises £100M for personalized T cell solid tumor trials | Achilles Therapeutics has raised a £100 million ($120 million) series B round. The financing sets Achilles up to run human proof-of-concept studies of its personalized T-cell therapies in two types of solid tumors. Syncona and Cancer Resear... |
| 01.11.2016 | Achilles Therapeutics Launches with £13.2M | Achilles Therapeutics, a London, UK-based newly formed developer of cancer immunotherapies, has launched with £13.2m in funding. The round was led by Syncona with the Cancer Research Technology (CRT) Pioneer Fund and The UCL Technology Fund... |